Key result
Diphenylhydantoin abolished re-entrant ventricular arrhythmias by selectively prolonging refractoriness and impairing conduction in ischemic cells of the re-entrant pathway.
Why the study?
Does diphenylhydantoin abolish re-entrant ventricular arrhythmias in a canine post-myocardial infarction model?
Does diphenylhydantoin abolish re-entrant ventricular arrhythmias in a canine post-myocardial infarction model?
Diphenylhydantoin abolishes re-entrant ventricular arrhythmias post-myocardial infarction by selectively depressing ischemic cells in the re-entrant pathway.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use in post-MI arrhythmias; leaves open translation of ischemia-selective effects to humans.
El‐Sherif et al. (1978) studied Re-entrant ventricular arrhythmias following myocardial infarction. Diphenylhydantoin (DPH) was evaluated on Mechanism of action on re-entrant ventricular arrhythmias. Diphenylhydantoin abolished re-entrant ventricular arrhythmias by selectively prolonging refractoriness and impairing conduction in ischemic cells of the re-entrant pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: